T cell compositions with improved phenotypic properties
US11007222B2 · kind B2 · utility
1Cited by
20References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2019 |
| Grant date | May 18, 2021 |
| Priority date | — |
| Expiry date | Dec 9, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.